RT Journal Article
T1 Selumetinib in the treatment of non-small-cell lung cancer
A1 Bernabe, Reyes
A1 Patrao, Ana
A1 Carter, Louise
A1 Blackhall, Fiona
A1 Dean, Emma
K1 MEK inhibitor
K1 non-small-cell lung cancer
K1 selumetinib
K1 Phase-ii trial
K1 Oral mek inhibitor
K1 Kras-mutant
K1 Open-label
K1 Azd6244 arry-142886
K1 Clinical-trial
K1 Plus docetaxel
K1 Multicenter
K1 Efficacy
K1 Chemotherapy
AB The RAS-RAF-MEK-ERK pathway regulates processes involved in the proliferation and survival of cells. KRAS mutations, prevalent in approximately 30% of patients with non-small-cell lung cancer ( NSCLC), result in constitutive activation of the pathway. Selumetinib ( AZD6244, ARRY-142886) is a potent and selective inhibitor of MEK1/2 which has demonstrated significant efficacy in combination with docetaxel in patients with KRAS mutant pretreated advanced NSCLC. Several trials in combination with other chemotherapy and targeted therapy regimens in lung cancer are ongoing. We review the development of selumetinib in patients with NSCLC, summarize the pharmacodynamic, pharmacokinetic and tolerability characteristics, and the available clinical trial data to understand the role of selumetinib in the treatment of NSCLC.
PB Future medicine ltd
SN 1479-6694
YR 2016
FD 2016-11-01
LK http://hdl.handle.net/10668/19200
UL http://hdl.handle.net/10668/19200
LA en
DS RISalud
RD Apr 7, 2025